Tarsus Pharmaceuticals (TARS) Stock Forecast, Price Target & Predictions
TARS Stock Forecast
Tarsus Pharmaceuticals stock forecast is as follows: an average price target of $62.00 (represents a 33.62% upside from TARS’s last price of $46.40) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
TARS Price Target
The average price target for Tarsus Pharmaceuticals (TARS) is $62.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $63.00 to $61.00. This represents a potential 33.62% upside from TARS's last price of $46.40.
TARS Analyst Ratings
According to 5 Wall Street analysts, Tarsus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for TARS stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Tarsus Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 23, 2024 | Francois Brisebois | Oppenheimer | $63.00 | $34.58 | 82.17% | 35.78% |
| May 13, 2024 | Oren Livnat | H.C. Wainwright | $61.00 | $37.00 | 64.86% | 31.47% |
The latest Tarsus Pharmaceuticals stock forecast, released on Sep 23, 2024 by Francois Brisebois from Oppenheimer, set a price target of $63.00, which represents a 82.17% increase from the stock price at the time of the forecast ($34.58), and a 35.78% increase from TARS last price ($46.40).
Tarsus Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $63.00 | $62.00 |
| Last Closing Price | $46.40 | $46.40 | $46.40 |
| Upside/Downside | -100.00% | 35.78% | 33.62% |
In the current month, the average price target of Tarsus Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Tarsus Pharmaceuticals's last price of $46.40. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 22, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Oct 11, 2024 | Guggenheim | Buy | Buy | Hold |
| Sep 23, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 10, 2024 | Barclays | Overweight | Overweight | Hold |
| May 09, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Feb 28, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 25, 2023 | William Blair | Outperform | Outperform | Hold |
Tarsus Pharmaceuticals's last stock rating was published by Oppenheimer on Oct 22, 2024. The company gave TARS a "Outperform" rating, the same as its previous rate.
Tarsus Pharmaceuticals Financial Forecast
Tarsus Pharmaceuticals Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $13.08M | $1.87M | $2.50M | $10.00M | - | $15.28M | $539.00K | $338.00K | $1.24M | $22.02M | $33.43M |
| Avg Forecast | $160.58M | $143.86M | $129.79M | $121.20M | $88.66M | $81.89M | $72.76M | $63.87M | $57.11M | $43.18M | $32.33M | $17.89M | $5.47M | $399.56K | $3.33M | $10.00M | $3.50M | $11.25M | $5.20M | $1.87M | $5.33M | $4.53M | $3.33M |
| High Forecast | $168.59M | $151.03M | $136.26M | $127.24M | $93.08M | $85.97M | $76.38M | $66.50M | $60.16M | $43.29M | $32.33M | $17.89M | $7.11M | $399.78K | $3.50M | $10.50M | $3.50M | $11.25M | $5.20M | $1.87M | $5.33M | $4.53M | $3.33M |
| Low Forecast | $151.57M | $135.79M | $122.51M | $114.40M | $83.68M | $77.30M | $68.67M | $61.24M | $52.54M | $43.08M | $32.33M | $17.89M | $2.54M | $399.34K | $3.15M | $9.44M | $3.50M | $11.25M | $5.20M | $1.87M | $5.33M | $4.53M | $3.33M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 2.39% | 4.68% | 0.75% | 1.00% | - | 1.36% | 0.10% | 0.18% | 0.23% | 4.86% | 10.03% |
Tarsus Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 4 analysts is $17.89M, with a low forecast of $17.89M, and a high forecast of $17.89M. TARS's average Quarter revenue forecast represents a 36.84% increase compared to the company's last Quarter revenue of $13.08M (Dec 23).
Tarsus Pharmaceuticals EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-44.45M | $-40.94M | $-22.65M | $-12.98M | $-21.76M | $-4.75M | $-19.04M | $-14.76M | $-15.96M | $6.50M | $10.80M |
| Avg Forecast | $-7.41M | $-6.64M | $-5.99M | $-5.60M | $-4.09M | $-3.78M | $-3.36M | $-2.95M | $-2.64M | $-1.99M | $-1.49M | $-826.24K | $-252.64K | $-18.45K | $-153.91K | $-461.75K | $-129.86K | $-417.39K | $-17.40M | $-69.23K | $-197.88K | $-168.19K | $-123.67K |
| High Forecast | $-7.00M | $-6.27M | $-5.66M | $-5.28M | $-3.86M | $-3.57M | $-3.17M | $-2.83M | $-2.43M | $-1.99M | $-1.49M | $-826.23K | $-117.31K | $-18.44K | $-145.28K | $-435.83K | $-129.86K | $-417.39K | $-13.92M | $-69.23K | $-197.88K | $-168.19K | $-123.67K |
| Low Forecast | $-7.78M | $-6.97M | $-6.29M | $-5.88M | $-4.30M | $-3.97M | $-3.53M | $-3.07M | $-2.78M | $-2.00M | $-1.49M | $-826.24K | $-328.48K | $-18.46K | $-161.59K | $-484.76K | $-129.86K | $-417.39K | $-20.88M | $-69.23K | $-197.88K | $-168.19K | $-123.67K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 175.94% | 2218.82% | 147.18% | 28.12% | 167.55% | 11.39% | 1.09% | 213.16% | 80.63% | -38.64% | -87.30% |
4 analysts predict TARS's average Quarter EBITDA for Sep 21 to be $-197.88K, with a high of $-197.88K and a low of $-197.88K. This is -103.04% lower than Tarsus Pharmaceuticals's previous annual EBITDA (Jun 21) of $6.50M.
Tarsus Pharmaceuticals Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-41.90M | $-39.15M | $-21.89M | $-13.08M | $-22.51M | $-6.26M | $-20.24M | $-14.85M | $-15.70M | $6.34M | $10.38M |
| Avg Forecast | $42.18M | $30.87M | $23.42M | $15.64M | $-7.15M | $-22.74M | $-23.12M | $-27.68M | $-29.72M | $-36.07M | $-35.43M | $-45.33M | $-52.66M | $-51.83M | $-36.69M | $-25.64M | $-36.31M | $-24.29M | $-17.68M | $-28.23M | $-15.79M | $-17.40M | $25.53M |
| High Forecast | $44.91M | $32.87M | $24.93M | $16.65M | $-6.63M | $-21.09M | $-21.43M | $-26.23M | $-19.69M | $-33.44M | $-32.84M | $-42.02M | $-44.98M | $-48.05M | $-34.02M | $-23.77M | $-36.31M | $-24.29M | $-14.14M | $-28.23M | $-15.79M | $-17.40M | $30.64M |
| Low Forecast | $39.10M | $28.62M | $21.71M | $14.50M | $-7.62M | $-24.22M | $-24.62M | $-29.14M | $-40.15M | $-38.41M | $-37.72M | $-48.26M | $-66.12M | $-55.19M | $-39.07M | $-27.30M | $-36.31M | $-24.29M | $-21.22M | $-28.23M | $-15.79M | $-17.40M | $20.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | 0.76% | 0.60% | 0.51% | 0.62% | 0.26% | 1.14% | 0.53% | 0.99% | -0.36% | 0.41% |
Tarsus Pharmaceuticals's average Quarter net income forecast for Sep 21 is $-15.79M, with a range of $-15.79M to $-15.79M. TARS's average Quarter net income forecast represents a -348.82% decrease compared to the company's last Quarter net income of $6.34M (Jun 21).
Tarsus Pharmaceuticals SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $43.01M | $30.32M | $15.10M | $14.63M | $11.99M | $10.38M | $7.95M | - | $6.67M | $6.79M | $5.16M |
| Avg Forecast | $334.55M | $299.71M | $270.41M | $252.50M | $184.71M | $170.61M | $151.58M | $133.07M | $118.98M | $89.97M | $67.36M | $37.28M | $11.40M | $832.42K | $6.94M | $20.83M | $7.29M | $23.44M | $10.83M | $3.89M | $11.11M | $9.44M | $6.94M |
| High Forecast | $351.23M | $314.65M | $283.89M | $265.09M | $193.92M | $179.11M | $159.13M | $138.54M | $125.34M | $90.19M | $67.36M | $37.28M | $14.82M | $832.88K | $7.29M | $21.87M | $7.29M | $23.44M | $10.83M | $3.89M | $11.11M | $9.44M | $6.94M |
| Low Forecast | $315.78M | $282.89M | $255.23M | $238.33M | $174.34M | $161.03M | $143.07M | $127.58M | $109.47M | $89.74M | $67.36M | $37.28M | $5.29M | $831.97K | $6.55M | $19.66M | $7.29M | $23.44M | $10.83M | $3.89M | $11.11M | $9.44M | $6.94M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.77% | 36.43% | 2.17% | 0.70% | 1.64% | 0.44% | 0.73% | - | 0.60% | 0.72% | 0.74% |
Tarsus Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $37.28M, based on 4 Wall Street analysts, with a range of $37.28M to $37.28M. The forecast indicates a -13.31% fall compared to TARS last annual SG&A of $43.01M (Dec 23).
Tarsus Pharmaceuticals EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $-0.82 | $-0.53 | $-0.84 | $-0.26 | $-0.98 | $-0.72 | $-0.76 | $0.31 | $0.51 |
| Avg Forecast | $1.10 | $0.80 | $0.61 | $0.41 | $-0.19 | $-0.59 | $-0.60 | $-0.72 | $-0.77 | $-0.94 | $-0.92 | $-1.18 | $-1.37 | $-1.35 | $-0.96 | $-0.67 | $-0.96 | $-0.64 | $-0.90 | $-0.75 | $-0.42 | $-0.46 | $-0.25 |
| High Forecast | $1.17 | $0.86 | $0.65 | $0.43 | $-0.17 | $-0.55 | $-0.56 | $-0.68 | $-0.51 | $-0.87 | $-0.86 | $-1.09 | $-1.17 | $-1.25 | $-0.89 | $-0.62 | $-0.96 | $-0.64 | $-0.90 | $-0.75 | $-0.42 | $-0.46 | $-0.25 |
| Low Forecast | $1.02 | $0.75 | $0.57 | $0.38 | $-0.20 | $-0.63 | $-0.64 | $-0.76 | $-1.05 | $-1.00 | $-0.98 | $-1.26 | $-1.72 | $-1.44 | $-1.02 | $-0.71 | $-0.96 | $-0.64 | $-0.90 | $-0.75 | $-0.42 | $-0.46 | $-0.25 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.86% | 0.79% | 0.88% | 0.40% | 1.08% | 0.96% | 1.82% | -0.67% | -2.03% |
According to 4 Wall Street analysts, Tarsus Pharmaceuticals's projected average Quarter EPS for Sep 21 is $-0.42, with a low estimate of $-0.42 and a high estimate of $-0.42. This represents a -234.65% decrease compared to TARS previous annual EPS of $0.31 (Jun 21).
Tarsus Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PEPG | PepGen | $4.32 | $29.50 | 582.87% | Buy |
| HOWL | Werewolf Therapeutics | $1.78 | $12.00 | 574.16% | Buy |
| OPT | Opthea | $3.13 | $14.00 | 347.28% | Buy |
| GNFT | Genfit | $4.24 | $13.00 | 206.60% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.31 | $7.00 | 203.03% | Buy |
| STOK | Stoke Therapeutics | $11.27 | $30.60 | 171.52% | Buy |
| NUVB | Nuvation Bio | $2.70 | $6.75 | 150.00% | Buy |
| ALDX | Aldeyra Therapeutics | $4.81 | $11.00 | 128.69% | Buy |
| TYRA | Tyra Biosciences | $15.36 | $31.75 | 106.71% | Buy |
| PHVS | Pharvaris | $21.04 | $39.67 | 88.55% | Buy |
| DSGN | Design Therapeutics | $5.57 | $9.67 | 73.61% | Buy |
| CNTB | Connect Biopharma | $0.99 | $1.50 | 51.52% | Buy |
| TARS | Tarsus Pharmaceuticals | $46.40 | $62.00 | 33.62% | Buy |
| CNTA | Centessa Pharmaceuticals | $18.19 | $23.25 | 27.82% | Buy |
| ETON | Eton Pharmaceuticals | $10.75 | $13.00 | 20.93% | Buy |
| NUVL | Nuvalent | $92.73 | $111.57 | 20.32% | Buy |
| TVTX | Travere Therapeutics | $18.26 | $21.75 | 19.11% | Buy |
| TRDA | Entrada Therapeutics | $18.05 | $20.00 | 10.80% | Buy |
| IKNA | Ikena Oncology | $1.73 | $1.33 | -23.12% | Buy |